MER-101
Adult Solid Cancers; Pediatric Sarcomas (e.g., Ewing Sarcoma)
Pre-clinicalActive
Key Facts
Indication
Adult Solid Cancers; Pediatric Sarcomas (e.g., Ewing Sarcoma)
Phase
Pre-clinical
Status
Active
Company
About Merlin Biotech
Merlin Biotech is a private, pre-clinical stage biotech leveraging mRNA and lipid nanoparticle (LNP) delivery to develop novel immunotherapies. The company's core focus is its lead asset, MER-101, which encodes the protein USP6 and is designed to activate multiple immunostimulatory pathways simultaneously to treat cancers. With a leadership team featuring veterans from Moderna and Nobel Laureates, Merlin aims to apply its platform to oncology, infectious diseases, and vaccines, though it remains pre-revenue and faces significant development and competitive risks inherent to the field.
View full company profile